[go: up one dir, main page]

PL2748151T3 - Pirymidynowe inhibitory pde10 - Google Patents

Pirymidynowe inhibitory pde10

Info

Publication number
PL2748151T3
PL2748151T3 PL12826375.3T PL12826375T PL2748151T3 PL 2748151 T3 PL2748151 T3 PL 2748151T3 PL 12826375 T PL12826375 T PL 12826375T PL 2748151 T3 PL2748151 T3 PL 2748151T3
Authority
PL
Poland
Prior art keywords
pde10 inhibitors
pyrimidine
pyrimidine pde10
inhibitors
pde10
Prior art date
Application number
PL12826375.3T
Other languages
English (en)
Inventor
Christopher D. Cox
Vadim Dudkin
Jeffrey Kern
Mark E. Layton
Izzat T. Raheem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2748151T3 publication Critical patent/PL2748151T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12826375.3T 2011-08-25 2012-08-20 Pirymidynowe inhibitory pde10 PL2748151T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161527392P 2011-08-25 2011-08-25

Publications (1)

Publication Number Publication Date
PL2748151T3 true PL2748151T3 (pl) 2016-09-30

Family

ID=47746797

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12826375.3T PL2748151T3 (pl) 2011-08-25 2012-08-20 Pirymidynowe inhibitory pde10

Country Status (37)

Country Link
US (1) US9062059B2 (pl)
EP (1) EP2748151B1 (pl)
JP (1) JP5648147B2 (pl)
KR (1) KR101655635B1 (pl)
CN (1) CN103917528B (pl)
AR (1) AR087628A1 (pl)
AU (1) AU2012299080B2 (pl)
BR (1) BR112014004310B8 (pl)
CA (1) CA2845578C (pl)
CL (1) CL2014000450A1 (pl)
CO (1) CO6890101A2 (pl)
CR (1) CR20140085A (pl)
CY (1) CY1117622T1 (pl)
DK (1) DK2748151T3 (pl)
DO (1) DOP2014000039A (pl)
EA (1) EA023685B1 (pl)
ES (1) ES2572527T3 (pl)
HK (1) HK1193410A1 (pl)
HR (1) HRP20160635T1 (pl)
HU (1) HUE028451T2 (pl)
IL (1) IL230997A (pl)
MA (1) MA35508B1 (pl)
ME (1) ME02419B (pl)
MX (1) MX357241B (pl)
MY (1) MY157301A (pl)
NI (1) NI201400014A (pl)
PE (1) PE20141535A1 (pl)
PH (1) PH12014500424A1 (pl)
PL (1) PL2748151T3 (pl)
RS (1) RS54788B1 (pl)
SG (1) SG2014013536A (pl)
SI (1) SI2748151T1 (pl)
TN (1) TN2014000070A1 (pl)
TW (1) TWI450895B (pl)
UA (1) UA109735C2 (pl)
WO (1) WO2013028590A1 (pl)
ZA (1) ZA201401272B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200001B2 (en) 2011-10-06 2015-12-01 Merck Sharp & Dohme Corp. Triazolyl PDE10 inhibitors
CA2851082A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
US9359348B2 (en) 2012-11-15 2016-06-07 Merck Sharp & Dohme Corp. Cyclopropyl imidazopyridine PDE10 inhibitors
TW201422610A (zh) 2012-11-15 2014-06-16 Merck Sharp & Dohme 作爲pde10抑制劑之經二級醇取代之三唑
WO2014078216A1 (en) 2012-11-15 2014-05-22 Merck Sharp & Dohme Corp. Cyclobutyl benzimidazoles as pde10 inhibitors
US9273033B2 (en) 2012-11-20 2016-03-01 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as PDE10 inhibitors
US9663513B2 (en) 2012-11-20 2017-05-30 Merck Sharp & Dohme Corp. Pyrimidine PDE10 inhibitors
WO2014139150A1 (en) * 2013-03-15 2014-09-18 Merck Sharp & Dohme Corp. Substituted pyridizinone derivatives as pde10 inhibitors
RS58509B1 (sr) 2014-03-24 2019-04-30 Novartis Ag Organska jedinjenja monobaktama za lečenje bakterijskih infekcija
JP7008704B2 (ja) * 2016-11-28 2022-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7478672B2 (ja) 2018-06-27 2024-05-07 エフ. ホフマン-ラ ロシュ アーゲー カンナビノイド受容体2の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
JP7445610B2 (ja) 2018-06-27 2024-03-07 エフ. ホフマン-ラ ロシュ アーゲー 医療に有用な新規化合物
CA3212082A1 (en) * 2021-03-17 2022-09-22 Merck Sharp & Dohme Llc Pro drugs of pde10 compounds
WO2023184486A1 (en) * 2022-04-01 2023-10-05 Merck Sharp & Dohme Llc Process for preparing ( (1s, 2s) -2- (5-methylpyridin-2-yl) cyclopropyl) -methanol
CN115403527B (zh) * 2022-07-20 2024-03-29 西安近代化学研究所 一种还原胺化法合成杀菌剂乙嘧酚的方法
WO2024049721A1 (en) * 2022-08-31 2024-03-07 Merck Sharp & Dohme Llc Sustained release delivery of a pde10 inhibitor
WO2024099135A1 (zh) * 2022-11-11 2024-05-16 杭州中美华东制药有限公司 1,5-萘啶类cGAS抑制剂及其用途
WO2024206200A1 (en) * 2023-03-29 2024-10-03 Merck Sharp & Dohme Llc Controlled release pde10a formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
EP1810411A2 (en) 2004-10-12 2007-07-25 Maxlinear, Inc. A receiver architecture with digitally generated intermediate frequency
KR100896380B1 (ko) 2005-01-07 2009-05-08 화이자 프로덕츠 인코포레이티드 헤테로방향족 퀴놀린 화합물 및 pde10 저해제로서의그의 용도
GB0506883D0 (en) * 2005-04-05 2005-05-11 Astrazeneca Ab Chemical compounds
US20080167297A1 (en) * 2005-04-05 2008-07-10 Astrazeneca Ab Pyrimidine Derivatives for Use as Anticancer Agents
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007129183A2 (en) 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
WO2010027097A1 (en) 2008-09-04 2010-03-11 Mitsubishi Tanabe Pharma Corporation Tri-substituted pyrimidine compounds and their use as pde10 inhibitors
WO2010030027A1 (en) * 2008-09-10 2010-03-18 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
AR074343A1 (es) * 2008-11-14 2011-01-12 Amgen Inc Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10
WO2010077992A1 (en) * 2008-12-17 2010-07-08 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
TWI481607B (zh) * 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
EP2621276B1 (en) 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
EP2621926B1 (en) * 2010-09-30 2017-08-30 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors

Also Published As

Publication number Publication date
AU2012299080B2 (en) 2016-03-17
BR112014004310A2 (pt) 2017-03-28
CL2014000450A1 (es) 2014-08-22
KR101655635B1 (ko) 2016-09-07
CN103917528B (zh) 2016-04-20
EA023685B1 (ru) 2016-06-30
MX2014002178A (es) 2014-05-01
JP2014524471A (ja) 2014-09-22
SG2014013536A (en) 2014-07-30
HRP20160635T1 (hr) 2016-07-01
NZ621245A (en) 2014-12-24
SI2748151T1 (sl) 2016-06-30
MX357241B (es) 2018-06-29
BR112014004310B8 (pt) 2023-04-18
AU2012299080A1 (en) 2014-03-06
WO2013028590A1 (en) 2013-02-28
ZA201401272B (en) 2017-09-27
EA201490492A1 (ru) 2014-06-30
EP2748151B1 (en) 2016-03-16
KR20140053356A (ko) 2014-05-07
HK1193410A1 (zh) 2014-09-19
TW201313699A (zh) 2013-04-01
TN2014000070A1 (en) 2015-07-01
CY1117622T1 (el) 2017-04-26
CO6890101A2 (es) 2014-03-10
ME02419B (me) 2016-09-20
DOP2014000039A (es) 2014-06-01
IL230997A (en) 2015-08-31
BR112014004310B1 (pt) 2022-03-03
HUE028451T2 (en) 2016-12-28
EP2748151A4 (en) 2015-01-07
EP2748151A1 (en) 2014-07-02
CA2845578C (en) 2016-02-16
MY157301A (en) 2016-05-31
US20140228368A1 (en) 2014-08-14
JP5648147B2 (ja) 2015-01-07
IL230997A0 (en) 2014-03-31
CR20140085A (es) 2014-05-02
DK2748151T3 (en) 2016-07-04
AR087628A1 (es) 2014-04-09
TWI450895B (zh) 2014-09-01
CN103917528A (zh) 2014-07-09
US9062059B2 (en) 2015-06-23
NI201400014A (es) 2014-07-25
PH12014500424A1 (en) 2016-08-03
MA35508B1 (fr) 2014-10-02
ES2572527T3 (es) 2016-06-01
CA2845578A1 (en) 2013-02-28
UA109735C2 (xx) 2015-09-25
PE20141535A1 (es) 2014-11-06
RS54788B1 (sr) 2016-10-31

Similar Documents

Publication Publication Date Title
HK1193410A1 (zh) 嘧啶 抑制劑
HK1222647A1 (zh) 激酶抑制劑
PL2710007T3 (pl) Inhibitory kinazy
IL231484A0 (en) Protein kinase inhibitors
PT2710005T (pt) Inibidores de tirosina-quinase
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2782580A4 (en) SELECTIVE INHIBITORS OF KINASES
IL232234A0 (en) Inhibitors of aminopyrimidine kinase
GB201016880D0 (en) Phosphodiesterase inhibitors
IL228928A0 (en) Aminopyrimidine kinase inhibitors
IL229028A0 (en) Kinase inhibitors
EP2785183A4 (en) TRIAZOLOPYRIDINONE PDE10 INHIBITORS
GB201009731D0 (en) Kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1199873A1 (en) Kinase inhibitors
HK1201460A1 (en) Pyrazine kinase inhibitors
GB201113689D0 (en) Novel PDE4 inhibitors
GB201120474D0 (en) Inhibitors
GB201223308D0 (en) Enzyme inhibitors